Contract Research & Services
Clinical Trials

Clinical Trials News

View news from other Pharmaceutical sectors:
211-225 of 4334 results
Heron initiates phase 3 program for HTX-011 in postoperative pain
Heron Therapeutics has reported positive outcome of a recent End-of-Phase 2 meeting with the US Food and Drug Administration (FDA) regarding its investigational agent, HTX-011, to prevent postoperative pain for the first 72 hours post surgery.
Contract Research & Services > Clinical Trials > News
Allegro’s Luminate succeeds in phase 2 diabetic macular edema trial
By PBR Staff Writer
Allegro Ophthalmics' Luminate integrin peptide therapy has passed a phase 2 trial in diabetic macular edema (DME) patients by meeting its primary endpoint when used as a sequential treatment.
Contract Research & Services > Clinical Trials > News
Cancer Research UK, Biotecnol to begin trials of novel immuno-oncology treatment
By PBR Staff Writer
Cancer Research UK has collaborated with Biotecnol to start early phase clinical trials for new immuno-oncology treatment, Tb535H.
Contract Research & Services > Clinical Trials > News
Amylyx Pharmaceuticals doses first patient in phase II clinical trial of AMX0035
Amylyx Pharmaceuticals, in collaboration with The ALS Association, ALS Finding a Cure, and the Massachusetts General Hospital, has dosed the first patient in the CENTAUR study, a Phase II clinical trial assessing the efficacy and safety of AMX0035 for the treatment of amyotrophic lateral sclerosis (ALS).
Contract Research & Services > Clinical Trials > News
Zynerba’s cannabis-based epilepsy gel fails in phase 2 trial
By PBR Staff Writer
Zynerba Pharmaceuticals has reported that its cannabis-based epilepsy gel ZYN002 (cannabidiol [CBD] gel) has failed to meet the primary point in a phase 2 clinical trial.
Contract Research & Services > Clinical Trials > News
Lilly’s migraine drug Lasmiditan succeeds in second phase 3 trial
By PBR Staff Writer
Eli Lilly's migraine drug Lasmiditan has met its primary endpoint in a second phase 3 trial.
Contract Research & Services > Clinical Trials > News
Orbsen gets European approval to start diabetic kidney disease trial for Obrcel-M
Orbsen Therapeutics’ stromal cell immunotherapy, OBRCEL-M has been approved to begin testing in a randomised, double blind, and placebo-controlled clinical trial in Europe to treat diabetic kidney disease.
Contract Research & Services > Clinical Trials > News
Flex Pharma launches ALS phase 2 study with FLX-787 in US
Flex Pharma has initiated a Phase 2 randomized, controlled, double-blinded, parallel design trial in the US.
Contract Research & Services > Clinical Trials > News
Merck, Generex to assess Keytruda in combination with AE37
Generex Biotechnology's subsidiary, Antigen Express has signed a clinical trial collaboration agreement with Merck, via a wholly-owned subsidiary, to assess Antigen’s AE37 cancer vaccine in combination with Merck’s anti-PD-1 (programmed death receptor-1) therapy, KEYTRUDA (pembrolizumab), in patients with metastatic triple-negative breast cancer.
Contract Research & Services > Clinical Trials > News
LabCorp to acquire clinical trials firm Chiltern for $1.2bn
By PBR Staff Writer
LabCorp has agreed to acquire specialty contract research organization (CRO) Chiltern for nearly $1.2bn in an all-cash deal to expand its oncology offerings.
Contract Research & Services > Clinical Trials > News
AstraZeneca's lung cancer immunotherapy trial fails to meet primary endpoint
By PBR Staff Writer
AstraZeneca’s Imfinzi (durvalumab) in combination with tremelimumab failed to improve progression-free survival (PFS) significantly in a phase 3 trial in previously untreated patients having advanced lung cancer.
Contract Research & Services > Clinical Trials > News
Merck’s Keytruda fails to improve survival in phase 3 head and neck cancer trial
By PBR Staff Writer
Merck’s anti-PD-1 therapy Keytruda (pembrolizumab) failed to improve overall survival (OS) in a pivotal phase 3 trial in head and neck squamous cell carcinoma (HNSCC) patients compared to standard treatment.
Contract Research & Services > Clinical Trials > News
Bayer's phase 2 clinical trial of monotherapy for second-line mesothelioma fails
Bayer’s phase 2 clinical study examining anetumab ravtansine as monotherapy in patients with recurrent malignant pleural mesothelioma did not meet the primary endpoint of progression-free survival.
Contract Research & Services > Clinical Trials > News
Brainstorm secures $16m grant for phase 3 trial of NurOwn in ALS
The California Institute for Regenerative Medicine (CIRM) has awarded a grant of $16m to Brainstorm Cell Therapeutics to support a phase 3 study of NurOwn for the treatment of amyotrophic lateral sclerosis (ALS).
Contract Research & Services > Clinical Trials > News
Alzheimer’s drug reduces hallmark inflammation related to metabolic syndrome by 25%
An existing Alzheimer’s medication has been found to cut inflammation and insulin resistance in patients with metabolic syndrome, as per new clinical trial results put up by scientists at Northwell Health’s The Feinstein Institute for Medical Research.
Contract Research & Services > Clinical Trials > News
211-225 of 4334 results